Company: JACS-RI
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0001013762-25-000620
Chunk: 143

Company: Jackson Acquisition Co II
Filing Date: 2025-03-18
Form: 10-K
Item: Item 1
Chunk 143
---
 of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with
one or more businesses (“Business Combination”).

While the Company may pursue an initial business
combination target in any industry or geographic location, the Company intends to focus its search for a target business by concentrating
its efforts in identifying high-quality businesses with a focus on healthcare services, healthcare technology, or otherwise focused on
the healthcare industry. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the
risks associated with early stage and emerging growth companies.

As of December 31, 2024, the Company had not commenced
any operations. All activity for the period from September 11, 2024 (inception) through December 31, 2024, relates to the Company’s
formation and the initial public offering (“Initial Public Offering”), which is described below. The Company will not generate
any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating
income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31
as its fiscal year end.

 The registration statement for the Company’s
Initial Public Offering was declared effective on December 9, 2024. On December 11, 2024, the Company consummated the Initial Public Offering
of 23,000,000 units (the “Units” and, with respect to the shares of Class A ordinary shares included in the Units being offered,
the “Public Shares”), which includes the full exercise by the underwriters of their over-allotment option in the amount of
3,000,000 Units, at $10.00 per Unit, generating gross proceeds of $230,000,000, which is described in Note 3. Simultaneously with the
closing of the Initial Public Offering, the Company consummated the sale of 840,000 private placement units (each, a “Private Placement
Unit”) at a price of $10.00 per Private Placement Unit in a private placement to RJ Healthcare SPAC II, LLC (“Sponsor”)
and Roth Capital Partners, LLC, representative of the underwriters (“Roth”), generating gross proceeds of $8,400,000, which
is described in Note 4.

Transaction costs amounted to $5,157,741, consisting
of $4,600,000 of